Valuable Targets

Unveiling the Secrets of IL-23 Inhibitors: Stay Updated with the Latest Advances

28 November 2023
4 min read

IL-23, or Interleukin-23, is a crucial cytokine that plays a significant role in the human body's immune response. It is primarily produced by activated antigen-presenting cells, such as dendritic cells and macrophages. IL-23 acts as a mediator between innate and adaptive immunity by stimulating the production of pro-inflammatory cytokines and promoting the differentiation and expansion of T-helper 17 (Th17) cells. Th17 cells, in turn, produce various cytokines that contribute to inflammation and immune responses against pathogens. However, dysregulation of IL-23 signaling has been associated with several autoimmune diseases, making it an important target for therapeutic interventions in the pharmaceutical industry.

Interleukin-23 (IL-23) inhibitors are a class of therapeutics that target the cytokine IL-23, which plays a crucial role in inflammation and autoimmune diseases. IL-23 was first discovered 20 years ago in an in silico bioinformatics search for novel members of the IL-6 cytokine family. The first agents targeting IL-23 to be investigated in humans were briakinumab and ustekinumab.

IL-23 inhibitors are expected to continue to play a significant role in the treatment of various diseases. They have shown promising results in treating serious cases of psoriasis and are also used widely for the treatment of rheumatoid arthritis. However, the emergence of resistance and the lack of an effective reversal drug when bleeding occurs are challenges that need to be addressed. Ongoing research and development efforts are focused on addressing these issues and expanding the clinical applications of IL-23 inhibitors. The approval of these drugs in more countries would further contribute to addressing the unmet medical needs of individuals with immune system diseases, digestive system disorders, and skin and musculoskeletal diseases.

The analysis of target IL-23 in the pharmaceutical industry reveals a competitive landscape with multiple companies actively developing drugs in various stages of development. Alvotech Swiss AG, Johnson & Johnson, Amgen, Inc., AstraZeneca PLC, Celltrion, Inc., and Biocon Ltd. are among the companies growing fastest under this target. Drugs targeting IL-23 have been approved for indications such as plaque psoriasis, arthritis psoriatic, and Crohn's disease. Monoclonal antibodies, biosimilars, and small molecule drugs are progressing most rapidly under this target, indicating intense competition. Japan, the United States, and China are the countries/locations developing fastest under this target, with China showing significant progress. Overall, the future development of target IL-23 in the pharmaceutical industry is promising, with a focus on innovative drugs and expanding indications.

How do they work?

IL-23 inhibitors are a type of medication that target and inhibit the activity of interleukin-23 (IL-23), which is a cytokine involved in the immune response. From a biomedical perspective, IL-23 inhibitors are used in the treatment of various autoimmune diseases, particularly those involving chronic inflammation, such as psoriasis and psoriatic arthritis. IL-23 plays a crucial role in the development and maintenance of these conditions by promoting the activation and proliferation of immune cells, leading to excessive inflammation.

By inhibiting IL-23, these inhibitors help regulate the immune response and reduce inflammation. They can be administered through different routes, such as subcutaneous injections or intravenous infusions, depending on the specific medication. IL-23 inhibitors have shown efficacy in improving symptoms and reducing disease progression in patients with autoimmune diseases associated with IL-23 dysregulation.

It is important to note that IL-23 inhibitors specifically target IL-23 and do not affect other cytokines or immune pathways. This targeted approach helps minimize potential side effects and provides a more tailored treatment option for patients with IL-23-driven autoimmune conditions. IL-23 inhibitors represent a significant advancement in biomedicine, offering new therapeutic options for managing chronic inflammatory diseases.

List of IL-23 Inhibitors

The currently marketed IL-23 inhibitors include:

For more information, please click on the image below.

What are IL-23 inhibitors used for?

IL-23 inhibitors have shown promising results in treating serious cases of psoriasis and are also used widely for the treatment of rheumatoid arthritis. For more information, please click on the image below to log in and search.

图片包含 图表

描述已自动生成

How to obtain the latest development progress of IL-23 inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of IL-23 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 表格

描述已自动生成

图形用户界面, 应用程序, Teams

描述已自动生成

Omnix Medical gets green light from U.S. FDA for Phase II testing of its advanced anti-infective agent OMN6
Latest Hotspot
3 min read
Omnix Medical gets green light from U.S. FDA for Phase II testing of its advanced anti-infective agent OMN6
28 November 2023
The biopharmaceutical company Omnix Medical, known for creating advanced anti-infectives to combat serious infections, has reported today that their upcoming Phase II trial for their innovative anti-infective, OMN6, has received approval from the FDA.
Read →
Revumenib: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ASH
Revumenib: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ASH
28 November 2023
The latest clinical findings of Revumenib will be unveiled at the 2023 ASH Congress, demonstrating its potential effect and setting the stage for subsequent investigations.
Read →
The OCEANIC-AF research was prematurely terminated due to insufficient effectiveness
Latest Hotspot
3 min read
The OCEANIC-AF research was prematurely terminated due to insufficient effectiveness
28 November 2023
The OCEANIC-AF phase III trial comparing asundexian and apixaban in stroke-risk atrial fibrillation patients will end early. This is based on the Independent Data Monitoring Committee's recommendation, as asundexian showed lower efficacy than the control. Bayer will analyze the data further and share the results later.
Read →
Unveiling the Secrets of LAG3 Inhibitors: Stay Updated with the Latest Advances
Unveiling the Secrets of LAG3 Inhibitors: Stay Updated with the Latest Advances
28 November 2023
The LAG-3 molecule can negatively requlate T cells and plays an important role in maintaining thestability of the immune system and promoting tumor immune escape. As one of the new targets, LAG-3has great potential in tumor immunotherapy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.